CODX - Co-Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.25
-0.04 (-1.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.29
Open2.31
Bid0.00 x 3000
Ask0.00 x 3000
Day's Range2.11 - 2.29
52 Week Range1.45 - 6.66
Volume22,867
Avg. Volume17,287
Market Cap27.783M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Co-Diagnostics, Guardant Health, and Others Included in Health Care Stocks Snapshot

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / The newly-patented CoPrimer™ technology, developed and made available by Co-Diagnostics, Inc. (CODX), has recently been the subject of review and comparison by the wall Street Club. With the Health Care Equipment and Supplies industry having seen over 15% growth so far in 2018, significantly outpacing the 5.57% growth of the S&P 500 Index, a number of companies were covered - all within the diagnostics sector. Guardant Health, Inc (GH) recently enjoyed an IPO and initial month trading that can best be described as wildly successful.

  • ACCESSWIRE18 days ago

    Co-Diagnostics, Inc. Signs ‘First of Many’ License Agreements for its CoPrimer Technology

    NEW YORK CITY, NY / ACCESSWIRE / November 1, 2018 / The newly-patented CoPrimer™ technology, developed and made available by Co-Diagnostics, Inc. (CODX), is the subject of a recent license agreement with LGC, Biosearch Technologies, the first such agreement to license the CoPrimers technology. In the agreement, the company agrees to license CoPrimers to LGC Biosearch, a global leader in the design, several development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets, on an exclusive basis for use in certain agricultural applications. Co-Diagnostics views the addition of CoPrimers to LGC's portfolio of products as a major validation of the quality of their technology.

  • Business Wire20 days ago

    Co-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and LGC, Biosearch Technologies, a global leader in the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets, announced today that they have signed an exclusive license agreement related to the use of the Company’s CoPrimer™ technology for both research and commercial applications. This Agreement is the result of a joint development project conducted over the past year to test the performance of CoPrimers in multiplexed reactions when locating specific genetic traits in seed products and genetic mutations, including SNP detection.

  • Business Wire21 days ago

    Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it will be offering a presentation of its mosquito vector control program at the 71st Annual Utah Mosquito Abatement Association conference in Ogden, Utah on October 29, 2018. From the website of the Utah Mosquito Abatement Association (UMAA), the UMAA was founded in 1948, with the goal of promoting close cooperation among those concerned with, or interested in mosquito control and related work, to increase the knowledge and advance the cause of mosquito abatement in an efficient and effective manner compatible with the goals of a sound environment.

  • ACCESSWIRE27 days ago

    World Health Organization & UNICEF Confirm High Demand for Zika Solutions in Co-Diagnostics Targeted Markets

    NEW YORK CITY, NY / ACCESSWIRE / October 23, 2018 / The need to identify and protect against Zika transmission and potential future epidemics not only still exists, but should addressed in a sustained, persistent manner among communities experiencing the virus, according to representatives from the World Health Organization (WHO). The regions threatened by Zika represent primary areas of focus for Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, who recently received the CE-marking approval for its Logix Smart™ Zika Test in anticipation offering an affordable diagnostic solution to meet this demand. Furthermore, spiraling demand for Zika virus testing also stems from government-led preparedness programs and support from international organizations including UNICEF.

  • Business Wirelast month

    Co-Diagnostics, Inc. Receives CE Mark for Zika Screening Test

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Zika Test technical file has obtained CE mark approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic (“IVD”) for the diagnosis of Zika virus in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.

  • ACCESSWIRElast month

    Co-Diagnostics, Inc. to Expand Technology Licensing Model After Patent Issuance

    NEW YORK CITY, NEW YORK / ACCESSWIRE / October 16, 2018 / The CoPrimer™ platform technology created by Co-Diagnostics, Inc. (CODX), a molecular diagnostics company that uses this unique, proprietary platform in the development of their own molecular diagnostic tests, has been granted patent protection by the United States Patent and Trademark Office, and is now being offered under license agreements with manufacturers and developers of molecular diagnostics in a broad array of industry segments. Once protected by patents, polymerase chain reaction ("PCR") technology can safely be licensed for use by companies that use PCR to design their own diagnostic or research products. Examples of such technology include Roche's TaqMan® probes (RHHBY), LNA® technology by Santaris Pharma, Scorpions® Probes by Sigma-Aldrich (acquired by Merck, MRK) and SYBR® Green, produced by a wholly-owned subsidiary of Thermo Fisher Scientific (TMO).

  • Business Wirelast month

    Co-Diagnostics Receives Patent for CoPrimer™ Technology

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it has been awarded a patent from the United States Patent and Trademark Office related to the Company’s CoPrimer™ platform technology. Dwight Egan, CEO of Co-Diagnostics, commented, “We are very pleased that the remarkable capabilities of our flagship technology has been awarded patent protection. Now that the groundbreaking work and advancements of our co-founder, Dr. Brent Satterfield, in the field of PCR technology have been officially recognized by the granting of this patent, the Company is prepared to begin offering CoPrimers as a platform technology under license agreements with manufacturers and developers of molecular diagnostics in a broad array of industry segments.

  • ACCESSWIRE2 months ago

    Co-Diagnostics, Inc. Offering its Primer Design Services to the Growing $7 Billion PCR Industry

    NEW YORK, NY / ACCESSWIRE / September 25, 2018 / The patent-pending CoPrimer™ platform technology of Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, is now available to enterprises and research institutions as a part of the company's CoDX Design™ services. Polymerase chain reaction (''PCR'') is a method of testing a plant, animal, or human subject to detect the existence of a genetic sequence, such as that belonging to a particular virus or bacteria, a human gene that predicts a high likelihood of cancer, or a plant gene that is associated with drought resistance. If the sample tests results are positive, it indicates that the target genetic material (the sequence of DNA or RNA belonging to the disease, bacteria, or gene) was present in the sample.

  • Business Wire2 months ago

    Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it will be presenting at the Fourth Annual Robins Equity Research Roundup, held September 25 – 26, 2018 near Portland, Oregon. The Equity Research Roundup is sponsored by Catalyst Research Management Group, RIA, to offer opportunities for portfolio, hedge, and mutual fund managers, individual investors, and retail brokers to become acquainted with up-and-coming public and private companies. In addition to company presentations from a range of industries, the conference will also facilitate company introductions to influential members of the investment community.

  • Business Wire2 months ago

    Co-Diagnostics Adds Central and South America to its List of International Target Markets

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it is expanding its list of international target markets with the completion of a trip to interested laboratories and potential future sales installations across Central America. As the Company approaches commercialization of selected molecular diagnostic tests, Latin America joins India and the Caribbean region as important target markets for its products. The purpose of the trip was to introduce Co-Diagnostics’ products to some of the establishments that have expressed interest in the Company’s infectious disease detection platform.

  • ACCESSWIRE2 months ago

    Ground Breaking Co-Diagnostics' CoPrimers(TM) Technology Advances SNP Detection

    Detecting these variations (known as single-nucleotide polymorphisms, or SNPs), is big business for many industries, and Co-Diagnostics, Inc.'s (CODX) CoPrimer™ platform technology may hold the key to all of them. Other SNPs are harmful, and being aware of genetic predispositions towards cancer, mental illness, or heart disease in advance can allow us to take the preventative measures required to improve our quality of life years before being diagnosed with a disease or illness. Medical applications of SNP detection include identifying the presence of cancer cells or cell-free genetic material in a tissue or liquid biopsy, and to determine the distinct type of cancer involved.

  • ACCESSWIRE3 months ago

    BDA International Release: Co-Diagnostics, Inc. Has A Real Growth Strategy And Is Planning Big For Its Diagnostics Technology

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Co-Diagnostics, Inc. (CODX), a molecular diagnostics company that develops, manufactures and markets cutting edge diagnostics technology, recently filed a Form S-3 shelf registration with the Securities and Exchange Commission ("SEC"). The registration is "put on the shelf," metaphorically speaking, allowing a simple format for securities to be registered sold at any point within the 3-year lifespan of the shelf registration statement. Fast growing med-tech companies such as Co-Diagnostics tend to need to raise capital at greater frequencies relative to companies in other industries, and the filing of the Registration follows previous statements from the Company alluding to accelerating the development of their suite of diagnostics tests along with an anticipated period of expansion.

  • Business Wire3 months ago

    Co-Diagnostics Announces Filing of S-3 Shelf Registration

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”) to sell up to an aggregate amount of $25 million of its shares, which amount shall be subject to securities regulations. This announcement follows the Company’s most recent Form 10Q filing and the closure of $2 Million in debt financing announced on Friday, Aug. 10, 2018, and other press releases concerning advancements in the Company’s SNP detection technology and the CE marking of its Logix Smart™ MTB test. Dwight Egan, Chief Executive Officer of Co-Diagnostics, commented, “This Form S-3 shelf registration statement enhances the Company’s financial flexibility in the event appropriate opportunities present themselves.

  • ACCESSWIRE3 months ago

    (CODX) BDA International Release: Fulfilment of Financing to Fast-Track Near Term Sales for Co-Diagnostics, Inc.

    BARCELONA, SPAIN / ACCESSWIRE / August 14, 2018 / Co-Diagnostics, Inc. (CODX), a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology, recently announced the closing of a non-convertible debt instrument for $2M. The Company will apply the incoming funds towards working capital, to expand distribution of its infectious disease testing products, and to immediately accelerate initiatives to develop multiplex screens for liquid biopsy cancer screening, blood-bank screening, and SNP detection with applications in several areas, including agriculture. The Company expects that this non-convertible debt financing on favorable terms gives them the runway need to advance their position in the infectious disease diagnostics market, liquid biopsy for cancer detection, and SNP detection for agricultural and other industries.

  • Business Wire3 months ago

    Co-Diagnostics Announces Closing of Debt Financing

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today the closing of a non-convertible debt instrument for $2M. The Company will apply the incoming funds towards working capital, to expand distribution of its infectious disease testing products, and to immediately accelerate initiatives to develop multiplex screens for liquid biopsy cancer screening, blood-bank screening, and SNP detection with applications in several areas, including agriculture. Liquid biopsy refers to diagnostic tools that allow detection of cancer using analysis of blood rather than tissue or tumor samples.

  • ACCESSWIRE4 months ago

    Free Technical Research on Agilent Technologies and Three More Medical Research Equities

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Laboratories & Research equities this morning: Agilent Technologies Inc. (NYSE: A), Co-Diagnostics Inc. (NASDAQ: CODX), Quest Diagnostics Inc. (NYSE: DGX), and Bruker Corp. (NASDAQ: BRKR).

  • ACCESSWIRE4 months ago

    BDA International Release: Co-Diagnostics Inc.: CE Markers and Anticipated Future Growth

    BARCELONA, SPAIN / ACCESSWIRE / July 25, 2018 / Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that has developed a unique, patented and patent-pending diagnostic testing technology. A Utah corporation headquartered in Salt Lake City, Utah, its primary business is to commercialize its technology through sales, development and licensing. The innovative technology is embodied in 5 patents granted and pending and certain trade secrets, which make DNA testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past.

  • ACCESSWIRE4 months ago

    Kivuto Launches Kivuto Cloud to Enhance Access to Adobe Creative Cloud Apps

    OTTAWA, ON / ACCESSWIRE / July 25, 2018 / Kivuto is pleased to announce the launch Kivuto Cloud, a new solution that simplifies and enhances management of Adobe Creative Cloud licenses for schools and ...

  • Business Wire4 months ago

    Co-Diagnostics Receives CE Mark for Tuberculosis Test Kit

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test has obtained CE mark approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic (“IVD”) for the diagnosis of tuberculosis in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval. The World Health Organization (WHO) confirms that as of 2016, the latest year for which data is available, tuberculosis (TB) is one of the top 10 causes of death globally, proving fatal to 1.7 million people, and is the leading killer of individuals infected with HIV.

  • Business Wire4 months ago

    Co-Diagnostics Completes Submission of CE Mark Registration for Tuberculosis Screening Test

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test technical file has been submitted for registration with the European Community, and that the CE marked in vitro diagnostic (“IVD”) is expected to be available for purchase early in August in markets that accept a CE mark as valid regulatory approval.

  • Business Wire5 months ago

    Co-Diagnostics, Inc. to Host Booth at CARPHA Conference

    Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that they will be hosting a booth at the 63rd Annual 2018 Caribbean Public Health Agency (CARPHA) Health Research Conference in St. Kitts & Nevis on June 14-16. Co-Diagnostics, Inc. CEO Dwight Egan remarked, “We are excited to be attending this important event following the recent advancement in our CoPrimers™ platform technology in multiplex tests for SNP detection and the announcement of our CoPrimer technology being used in a research project conducted by the Wang Group at Stanford University.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: Co-Diagnostics and Valeant Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Both Co-Diagnostics and Valeant Pharmaceuticals saw big gains on Tuesday despite one not even having any news. Co-Diagnostics leaped ahead after announcing an ...

  • Business Wire5 months ago

    Co-Diagnostics, Inc. Announces Advancement of Co-Primers™ Technology in Multiplex SNP Genotyping

    Co-Diagnostics, Inc. (CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today an advancement in the Company’s Co-Primer™ platform technology in multiplex tests for SNP detection, which allows for multiple targets to be identified in a single reaction without costly and time-consuming re-optimization of primers. SNP detection refers to finding small-scale but clinically-significant mutations in a given gene using real-time polymerase chain reaction (PCR) testing. Medical applications of SNP detection include identifying the presence of cancer cells or cell-free genetic material in a liquid or tissue biopsy, and to determine the distinct type of cancer involved.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Stocks to Watch: Co-Diagnostics and Jaguar Health

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Shares of Co-Diagnostics Inc. was exploding on Friday after the company announced its CoPrimer™ technology is being employed to achieve the objectives of a research ...